Efficacy and safety of anti-vascular endothelial growth factor agents on corneal neovascularization: A meta-analysis

Table 2 Assessment of risk of bias

RoB 2.0 for randomized controlled trials
			D1	D2	D3	D4	D5	All
Bhatti et al[15]			H1	SC3	H5	L	H7	H
Dohlman et al[16]			L	L	L	L	L	L
Fasciani et al[17]			SC2	SC3	SC6	L	L	H
Hamdan et al[18]			SC2	L	L	L	L	SC
Kim et al[19]			SC2	L	L	L	L	SC
Li et al[20]			H1	L	SC6	L	L	H
Ozgurhan et al[21]			SC2	SC4	L	L	L	SC
Petsoglou et al[22]			L	L	L	L	L	L
You et al[23]			SC2	L	L	L	L	SC
D1: Bias arising from the randomization process
D2: Bias due to deviations from intended interventions
D3: Bias due to missing outcome data
D4: Bias in measurement of the outcome
D5: Bias in selection of the reported result
ROBINS-I for non-randomized studies
	D1	D2	D3	D4	D5	D6	D7	All
Huang et al[24]	L	L	L	L	M6	L	L	M
Hurmeric et al[25]	M8	L	L	L	L	L	S9	S
Trufanov et al[26]	M8	L	L	L	M6	L	S9	S
D1: Bias due to confounding
D2: Bias in selection of participants into the study
D3: Bias in classification of interventions
D4: Bias due to deviations from intended interventions
D5: Bias due to missing data
D6: Bias in measurement of outcomes
D7: Bias in selection of the reported result

¹Allocation sequence not concealed.

²Imbalance baseline or no information on allocation sequences.

³Open-labeled without information on deviation.

⁴No information on blinding or deviation.

⁵Missing data without descriptions.

⁶No information on missing data.

⁷Incomplete results.

⁸Apropriate analysis not conducted to control for confounding.

⁹Statistical analysis not conducted

H: High; S: Serious; SC: Some concerns; M: Moderate; L: Low.